CClinicalTrials.gg
WithdrawnNCT04561414IRISUpdated Apr 12, 2021

Objective to Evaluate the Safety and Effectiveness of LED Light Source System for Endoscopy in Ureteral Radiography

An interventional study of LED light source system for endoscope and Ureteral stent (Cook Ireland Ltd.) in Lower Abdominal Surgery and Pelvic Surgery, sponsored by Stryker Orthopaedics. Withdrawn at 4 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-04-12.

Sponsored by Stryker Orthopaedics · Not applicable, Interventional, and Diagnostic

Why this study was withdrawn
Study was registered but never started.
Phase
Not applicable
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This clinical trial is a prospective, multi-center, single-blind, parallel, randomized controlled superiority clinical trial. The trial will be carried out in 5 centers, involving 120 subjects as estimated who will be divided into the test group or control group randomly on an equal basis (each group includes 60 subjects).

This trial will be carried out in 4 stages, including the screening period, random grouping, operation date and follow-up period. In the screening period, the informed consent forms are collected and candidates are screened; after screening, the accepted subjects will be randomly divided into the control group or test group; on the operation date, the operation is carried out using the device tested; safety follow-up visit is carried out during the follow-up period.

Read the detailed description

The prospective, multi-center, single-blind, parallel, randomized controlled superiority trial design is adopted to evaluate the safety and effectiveness of the LED light source system for endoscope during ureter transillumination. The trial will be carried out in 5 centers, with the competitive grouping mode adopted. This trial will be carried out in the General Surgery Department and the Gynecology Department. Totally 120 subjects with rectal cancer, endometriosis, cervical cancer, adenomyosis and pelvic adhesion requiring operation (60 subjects for each of the test group and control group) are involved. The subjects, after signing the informed consent form approved by the Ethics Committee, will be screened by the investigators. Qualified subjects who meet all the inclusion criteria and do not meet any of the exclusion criteria will be randomly divided into the control group or the test group. The subjects in the control group will accept the ureteral stent (manufacturer: Cook Ireland Ltd.) during operation. The subjects in the test group will undergo surgery using the LED light source system for endoscope and the supporting IRIS ureter kit. On the operation date, the investigators will score the performance using a scale to evaluate the resolution of the ureter in the whole process of operation. During the follow-up period, the investigators will evaluate the safety of the device based on the results of vital signs, physical examination, blood routine examination, routine urine examination, blood biochemistry, 12-lead ECG and B-mode ultrasonography of urinary system.

02

Conditions studied

  • Lower Abdominal Surgery
  • Pelvic Surgery

Keywords

  • rectal cancer
  • endometriosis
  • cervical cancer
  • adenomyosis
  • pelvic adhesion
03

In context

Lead sponsor

Stryker Orthopaedics is the lead sponsor of 44 studies on the registry; 1 is open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 5 (100%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. The surgeon believes preventative placement of a ureteral stent is necessary and the target organ to be excised in the surgery is closely related to the ureter (e.g. representative specialized operations such as rectal cancer and endometriosis, cervical cancer, adenomyosis and pelvic adhesion).

    1. Age: 18 to 80 years old;
    2. All subjects voluntarily participate in the clinical trial and are asked to sign the informed consent form.

Exclusion criteria

  1. Women during pregnancy or lactation;

    1. Subjects are involved in other clinical trials at the same time; Hydronephrosis due to urinary tract obstruction; Laparotomy is expected (except for conversion to laparotomy during operation);
    2. Other conditions deemed by the investigators as unsuitable for operation;
    3. Other conditions deemed by the investigators as unsuitable for the trial (including anticipated catheterizing failure).
05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
0 participants (actual)

Study arms

  • Other
    LED light source system for endoscope

    The prospective, multi-center, single-blind, parallel, randomized controlled superiority trial design is adopted to evaluate the safety and effectiveness of the LED light source system for endoscope during ureter transillumination. The trial will be carried out in 5 centers, with the competitive grouping mode adopted. This trial will be carried out in the General Surgery Department and the Gynecology Department. Totally 120 subjects with rectal cancer, endometriosis, cervical cancer, adenomyosis and pelvic adhesion requiring operation (60 subjects for each of the test group and control group) are involved. The test group use LED light source system for endoscope

    Device: LED light source system for endoscope

  • Other
    Ureteral stent (Cook Ireland Ltd.)

    The prospective, multi-center, single-blind, parallel, randomized controlled superiority trial design is adopted to evaluate the safety and effectiveness of the LED light source system for endoscope during ureter transillumination. The trial will be carried out in 5 centers, with the competitive grouping mode adopted. This trial will be carried out in the General Surgery Department and the Gynecology Department. Totally 120 subjects with rectal cancer, endometriosis, cervical cancer, adenomyosis and pelvic adhesion requiring operation (60 subjects for each of the test group and control group) are involved. The control group use Ureteral stent (Cook Ireland Ltd.)

    Device: Ureteral stent (Cook Ireland Ltd.)

Interventions

  • DeviceLED light source system for endoscope

    The prospective, multi-center, single-blind, parallel, randomized controlled superiority trial design is adopted to evaluate the safety and effectiveness of the LED light source system for endoscope during ureter transillumination. The trial will be carried out in 5 centers, with the competitive grouping mode adopted. This trial will be carried out in the General Surgery Department and the Gynecology Department. Totally 120 subjects with rectal cancer, endometriosis, cervical cancer, adenomyosis and pelvic adhesion requiring operation (60 subjects for each of the test group and control group) are involved. The test group use LED light source system for endoscope.

  • DeviceUreteral stent (Cook Ireland Ltd.)

    The prospective, multi-center, single-blind, parallel, randomized controlled superiority trial design is adopted to evaluate the safety and effectiveness of the LED light source system for endoscope during ureter transillumination. The trial will be carried out in 5 centers, with the competitive grouping mode adopted. This trial will be carried out in the General Surgery Department and the Gynecology Department. Totally 120 subjects with rectal cancer, endometriosis, cervical cancer, adenomyosis and pelvic adhesion requiring operation (60 subjects for each of the test group and control group) are involved. The test group use Ureteral stent (Cook Ireland Ltd.).

06

What researchers measure

Primary outcomes

  1. Resolution of the ureter in the whole operation.

    On the operation date, the investigators will score the performance using a scale (1 very good - 10 worst outcome) to evaluate the resolution of the ureter in the whole process of operation.

    Time frame: in the whole process of operation

07

Study locations

4 sites
  • Beijing Chao-Yang Hospital,Capital Medical University
    Beijing, Beijing 100000, China
  • Xuanwu Hospital, Capital Medical University
    Beijing, Beijing 100000, China
  • The First Affiliated Hospital of Jilin University
    Jilin, Changchun 130000, China
  • Obstetrics&Gynecology Hospital of Fudan University
    Shanghai, Shanghai 200011, China
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 12, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04561414
Lead sponsor
Stryker Orthopaedics
Responsible party
Sponsor
First posted
Sep 23, 2020
Start date
May 2021 (estimated)
Primary completion
May 2021 (estimated)
Completion
May 2022 (estimated)
Last update
Apr 12, 2021

Study contacts

Zhongtao Zhang
principal investigator · Beijing Friendship Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion